CRVS

4.99

1.96% -0.10

Dopo l'orario di chiusura: 5.01 0.02 +0.40%

Corvus Pharmaceuticals Inc (CRVS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$5.09

Aprire:

$5.02

Volume 24 ore:

2.57M

Relative Volume:

2.45

Capitalizzazione di mercato:

$320.64M

Reddito:

Utile/perdita netta:

$-27.03M

Rapporto P/E:

-5.9405

EPS:

-0.84

Flusso di cassa netto:

$-23.97M

1 W Prestazione:

-32.38%

1M Prestazione:

-39.44%

6M Prestazione:

+161.26%

1 anno Prestazione:

+219.87%

Intervallo 1D:

$4.73

$5.34

Intervallo di 1 settimana:

$3.7701

$7.44

Portata 52W:

$1.30

$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Nome

Corvus Pharmaceuticals Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

(650) 900-4520

Indirizzo

863 MITTEN ROAD, BURLINGAME, CA

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

CRVS's Discussions on Twitter

Confronta CRVS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CRVS Corvus Pharmaceuticals Inc	4.99	320.64M	0	-27.03M	-23.97M	-0.56
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-08-18	Iniziato	Oppenheimer	Outperform
2021-12-01	Ripresa	Jefferies	Buy
2021-05-27	Iniziato	Cantor Fitzgerald	Overweight
2021-02-10	Downgrade	Mizuho	Buy → Neutral
2019-09-12	Iniziato	Mizuho	Buy
2019-05-29	Iniziato	ROTH Capital	Buy
2017-08-24	Aggiornamento	Credit Suisse	Underperform → Neutral
2017-05-01	Downgrade	Credit Suisse	Neutral → Underperform
2016-04-18	Iniziato	Credit Suisse	Outperform
2016-04-18	Iniziato	Guggenheim	Buy

Mostra tutto

Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie

Dec 20, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Announces Interim Data from Atopic Dermatitis TrialBURLINGAME, Calif. – Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) disclosed key interim data from its randomized, double-blind, placebo-controlled Phase 1 cl - Defense World

Dec 20, 2024

Dec 19, 2024

Corvus: Early Atopic Dermatitis Data Signals More Questions Than Answers (Rating Downgrade) - Seeking Alpha

Dec 19, 2024

Corvus Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:CRVS) - Defense World

Dec 19, 2024

Dec 18, 2024

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? - AOL

Dec 18, 2024

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting (CRVS) - Seeking Alpha

Dec 18, 2024

Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga

Dec 18, 2024

Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga

Dec 18, 2024

Stock Traders Buy High Volume of Put Options on Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat

Dec 18, 2024

Corvus stock falls after eczema trial data (CRVS:NASDAQ) - Seeking Alpha

Dec 18, 2024

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Dec 18, 2024

Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost - TipRanks

Dec 18, 2024

Corvus Pharmaceuticals Shares Surge 7% After Positive Phase 1 Trial Results for Soquelitinib in Atopic Dermatitis - mediahousepress

Dec 18, 2024

Corvus Pharmaceuticals stock falls despite promising early trial results - Investing.com

Dec 18, 2024

Corvus Pharmaceuticals Announces Interim Data from - GlobeNewswire

Dec 18, 2024

Form 8-K Corvus Pharmaceuticals, For: Dec 18 - StreetInsider.com

Dec 18, 2024

Corvus Pharma's Atopic Dermatitis Drug Shows Promising 69% Efficacy in Phase 1 Trial Data - StockTitan

Dec 18, 2024

Why US Futures Are Rising WednesdayCorvus Pharma (NASDAQ:CRVS), Applied DNA Sciences (NASDAQ:APDN) - Benzinga

Dec 18, 2024

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga

Dec 18, 2024

Dec 17, 2024

Corvus to share soquelitinib trial data for skin condition By Investing.com - Investing.com Australia

Dec 17, 2024

Corvus to share soquelitinib trial data for skin condition - Investing.com India

Dec 17, 2024

Stocks to Watch: Worthington Enterprises, Corvus Pharmaceuticals, CommScope Holding - MarketWatch

Dec 17, 2024

Corvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data Reveal - MarketWatch

Dec 17, 2024

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 - The Manila Times

Dec 17, 2024

Corvus Pharma Set to Unveil Key Atopic Dermatitis Trial Data for Soquelitinib in December - StockTitan

Dec 17, 2024

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Sees Large Increase in Short Interest - MarketBeat

Dec 17, 2024

Dec 11, 2024

Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16% - Yahoo Finance

Dec 11, 2024

Dec 10, 2024

Trading (CRVS) With Integrated Risk Controls - Stock Traders Daily

Dec 10, 2024

Dec 06, 2024

Point72 Asset Management L.P. Decreases Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat

Dec 06, 2024

Dec 05, 2024

Individual investors are Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) biggest owners and were hit after market cap dropped US$89m - Simply Wall St

Dec 05, 2024

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity - The Manila Times

Dec 05, 2024

Dec 04, 2024

CRVSCorvus Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Dec 04, 2024

Corvus Pharma's Cancer Drug Shows Breakthrough Immune Response in Nature Journal Study - StockTitan

Dec 04, 2024

Nov 29, 2024

Connor Clark & Lunn Investment Management Ltd. Grows Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat

Nov 29, 2024

Nov 18, 2024

Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 18, 2024

FY2024 EPS Estimates for CRVS Cut by Cantor Fitzgerald - MarketBeat

Nov 18, 2024

Nov 16, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Large Volume IncreaseWhat's Next? - MarketBeat

Nov 16, 2024

Nov 14, 2024

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2024 Earnings Call Transcript - MSN

Nov 14, 2024

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Towerview LLC - MarketBeat

Nov 14, 2024

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis - The Manila Times

Nov 14, 2024

Corvus drug shows promise in systemic sclerosis models - Investing.com

Nov 14, 2024

Corvus' Soquelitinib Shows Promise in Preventing Systemic Sclerosis Lung Damage in Key Study | CRVS Stock News - StockTitan

Nov 14, 2024

Nov 13, 2024

Corvus Pharmaceuticals target raised to $13 by Jefferies - Investing.com UK

Nov 13, 2024

Corvus Pharmaceuticals: The Market Likes The Story (NASDAQ:CRVS) - Seeking Alpha

Nov 13, 2024

Earnings call: Corvus Pharmaceuticals reports Q3 financials and trial updates - Investing.com

Nov 13, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Given New $14.00 Price Target at Oppenheimer - MarketBeat

Nov 13, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up Following Analyst Upgrade - MarketBeat

Nov 13, 2024